Archived article

Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.

The pharma giant has a tough year ahead after losing patent protection on major drug
Thursday 20 Apr 2017 Author: Lisa-Marie Janes

Thursday 27 April

Investors are already forewarned of a tough 2017 for pharmaceutical business  AstraZeneca (AZN) after guidance in February for a low to mid-single digit sales decline.

We believe investors will want an update on cholesterol treatment Crestor in its trading update on 27 April after a 13% drop in sales following patent expiry.

The market will also be looking for clarity on which new drugs it will bring to market to replenish its portfolio.

‹ Previous2017-04-20Next ›